Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19

HOS-110533 · Präparat HOS-093385

18  Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with 245 mg (dose in mg) Cmax, Cmin tenofovir disoproxil Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma concentrations Voxilaprevir (400 mg/100 mg/ AUC: ↔ of tenofovir resulting from co- 100 mg+100 mg q.d.)3 + Darunavir Cmax: ↓ 30% administration of tenofovir (800 mg q.d.) + Ritonavir (100 mg Cmin: N/A disoproxil, q.d.) + Emtricitabine/Tenofovir sofosbuvir/velpatasvir/voxilaprevir disoproxil (200 mg/245 mg q.d.) GS-3310072: and darunavir/ritonavir may AUC: ↔ increase adverse reactions related Cmax:↔ to tenofovir disoproxil, including Cmin: N/A renal disorders. The safety of tenofovir disoproxil Velpatasvir: when used with AUC: ↔ sofosbuvir/velpatasvir/voxilaprevir Cmax: ↔ and a pharmacokinetic enhancer Cmin: ↔ (e.g. ritonavir or cobicistat) has not been established. Voxilaprevir: AUC: ↑ 143% The combination should be used Cmax:↑ 72% with caution with frequent renal Cmin: ↑ 300% monitoring (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)